AWH - Aspira Women's Health Announces $1.935 Million Private Placement Equity Financing | Benzinga
AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1,264,739 shares of its common stock ("Common Stock") and warrants to purchase an equal number of shares of Common Stock ("Warrants") at a combined offering price of $1.53 per share and warrant through a private placement financing (the "Offering"). Aspira anticipates the gross proceeds from the Offering will be approximately $1.935 million, before deducting offering expenses. The warrants will be exercisable for three years after date of issuance and have an exercise price of $2.25 per share. The Offering is expected to close by July 8, 2024 subject to customary closing conditions. Net proceeds from the Offering will support Aspira's ongoing commercial activities as well as general corporate purposes and working capital.
"The strong participation in this financing by our existing shareholders demonstrates firm support for Aspira at an important point in our growth," said Nicole Sandford, Aspira's CEO. "We are laser-focused on commercial growth following the expansion of our OvaSuite test portfolio and the publication of compelling clinical data earlier this quarter. We believe we are well on our way to changing the standard of care for the 1.2 to 1.5 million U.S. women diagnosed with an adnexal mass each year."
The securities being issued and sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States except ...